Redefining preeclampsia using placenta-derived biomarkers

Hypertension

Volumn 61, Issue 5, 2013, Pages 932-942

  Staff, Anne Cathrine ^a   Benton, Samantha J ^b   Von Dadelszen, Peter ^b   Roberts, James M ^d   Taylor, Robert N ^e   Powers, Robert W ^d   Charnock Jones, D Stephen ^f   Redman, Christopher W G ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

HUMAN; HYPERTENSION; NECROSIS; OXIDATIVE STRESS; PATHOGENESIS; PLACENTA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SPIRAL ARTERY THROMBOSIS; THROMBOSIS; TROPHOBLAST; VASCULITIS;

ANGIOGENESIS INHIBITORS; BIOLOGICAL MARKERS; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84876673839     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00250     Document Type: Review

References (162)

1. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 1988;158: 80-83.
2. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012;36:56-59.
3. Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull. 2003;67:161-176.
4. Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. J Pregnancy. 2011;2011:214365.
5. Carty DM, Delles C, Dominiczak AF. Preeclampsia and future maternal health. J Hypertens. 2010;28:1349-1355.
6. Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia. Front Biosci. 2007;12:2395-2402.
7. Nelson TR. A clinical study of pre-eclampsia. I. J Obstet Gynaecol Br Emp. 1955;62:48-57.
8. Davey DA, MacGillivray I. The classifcation and defnition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988;158: 892-898
9. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002;77:67-75.
10. von Dadelszen P, Magee LA, Roberts JM. Subclassifcation of preeclamp-sia. Hypertens Pregnancy. 2003;22:143-148
11. Management of hypertension in pregnancy: executive summary. Australasian Society for the Study of Hypertension in Pregnancy. Med J Aust. 1993;158:700-702.
12. Magee LA, Helewa M, Moutquin JM, von Dadelszen P; Hypertension Guideline Committee; Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 suppl):S1-48.
13. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common defnitions of hypertension in pregnancy. Obstet Gynecol. 2001;97:261-267.
14. Redman CW, Denson KW, Beilin LJ, Bolton FG, Stirrat GM. Factor-VIII consumption in pre-eclampsia. Lancet. 1977;2:1249-1252.
15. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994;309:1395-1400.
16. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103(5 pt 1):981-991.
17. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal infammatory response to pregnancy. Am J Obstet Gynecol. 1999;180 (2 pt 1):499-506.
18. Belo L, Santos-Silva A, Caslake M, Cooney J, Pereira-Leite L, Quintanilha A, Rebelo I. Neutrophil activation and C-reactive protein concentration in preeclampsia. Hypertens Pregnancy. 2003;22:129-141.
19. Greer IA, Haddad NG, Dawes J, Johnston TA, Johnstone FD, Steel JM. Increased neutrophil activation in diabetic pregnancy and in nonpregnant diabetic women. Obstet Gynecol. 1989;74:878-881.
20. Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-infammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet. 2001; 75:243-249.
21. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, Clark P, Walker ID, Sattar N, Greer IA. Short-and long-term changes in plasma infammatory markers associated with preeclampsia. Hypertension. 2004;44:708-714.
22. Gill R, Tsung A, Billiar T. Linking oxidative stress to infammation: tolllike receptors. Free Radic Biol Med. 2010;48:1121-1132.
23. Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665-673.
24. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta. 2009;30 suppl A:S38-S42.
25. Hubel CA, Roberts JM, Taylor RN, Musci TJ, Rogers GM, McLaughlin MK. Lipid peroxidation in pregnancy: new perspectives on preeclampsia. Am J Obstet Gynecol. 1989;161:1025-1034.
26. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet. 1994;343:645-646.
27. Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clin Sci. 1996;91:711-718.
28. Harsem NK, Braekke K, Staff AC. Augmented oxidative stress as well as antioxidant capacity in maternal circulation in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2006;128:209-215.
29. Chun D, Braga C, Chow C, Lok L. Clinical observations on some aspects of hydatidiform moles. J Obstet Gynaecol Br Commonw. 1964;71:180-184.
30. Piering WF, Garancis JG, Becker CG, Beres JA, Lemann J Jr. Preeclampsia related to a functioning extrauterine placenta: report of a case and 25-year follow-up. Am J Kidney Dis. 1993;21:310-313.
31. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol. 1999;23:45-57.
32. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for utero-placental blood fow during human pregnancy. Placenta. 2009;30:473-482.
33. Staff AC, Dechend R, Pijnenborg R. Learning from the placenta: acute ath-erosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health. Hypertension. 2010;56:1026-1034.
34. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 1991;98:648-655.
35. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and pro-teinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
36. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649.
37. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;122:33-39.
38. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177-182.
39. Bates DO. An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochem Soc Trans. 2011;39:1576-1582.
40. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200-1204.
41. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol. 1996;175:1365-1370.
42. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63:534-543.
43. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594.
44. Labarrere CA. Acute atherosis. A histopathological hallmark of immune aggression? Placenta. 1988;9:95-108.
45. Harsem NK, Roald B, Braekke K, Staff AC. Acute atherosis in decidual tissue: not associated with systemic oxidative stress in preeclampsia. Placenta. 2007;28:958-964.
46. Belo L, Caslake M, Gaffney D, Santos-Silva A, Pereira-Leite L, Quintanilha A, Rebelo I. Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis. 2002;162:425-432.
47. Zeek PM, Assali NS. Vascular changes in the decidua associated with eclamptogenic toxemia of pregnancy. Am J Clin Pathol. 1950;20:1099-1109.
48. Khong TY. Acute atherosis in pregnancies complicated by hypertension, small-for-gestational-age infants, and diabetes mellitus. Arch Pathol Lab Med. 1991;115:722-725.
49. Nayar R, Lage JM. Placental changes in a frst trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol. 1996;27:201-206.
50. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007;219:187-203.
51. Burton GJ, Charnock-Jones DS, Jauniaux E. Regulation of vascular growth and function in human placenta. Reproduction. 2009;138:895-902.
52. Brosens I, Renaer M. On the pathogenesis of placental infarcts in pre-eclampsia. J Obstet Gynaecol Br Commonw. 1972;79:794-799.
53. Khong TY, Mott C. Immunohistologic demonstration of endothelial disruption in acute atherosis in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 1993;51:193-197.
54. Jones CJ, Fox H. An ultrastructural and ultrahistochemical study of the human placenta in maternal pre-eclampsia. Placenta. 1980;1:61-76.
55. Yung HW, Calabrese S, Hynx D, Hemmings BA, Cetin I, Charnock-Jones DS, Burton GJ. Evidence of placental translation inhibition and endoplas-mic reticulum stress in the etiology of human intrauterine growth restriction. Am J Pathol. 2008;173:451-462.
56. Hung TH, Burton GJ. Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol. 2006;45:189-200.
57. Johnson RD, Polakoski KL, Huang X, Sadovsky Y, Nelson DM. The release of 15-hydroxyeicosatetraenoic acid by human placental trophoblast is increased in preeclampsia. Am J Obstet Gynecol. 1998;178(1 pt 1):54-58.
58. Mitchell MD, Koenig JM. Increased production of 15-hydroxyeico satetraenoic acid by placentae from pregnancies complicated by pregnancy-induced hypertension. Prostaglandins Leukot Essent Fatty Acids. 1991;43:61-62.
59. Staff AC, Halvorsen B, Ranheim T, Henriksen T. Elevated level of free 8-iso-prostaglandin F2alpha in the decidua basalis of women with pre-eclampsia. Am J Obstet Gynecol. 1999;181(5 pt 1):1211-1215.
60. Staff AC, Ranheim T, Khoury J, Henriksen T. Increased contents of phos-pholipids, cholesterol, and lipid peroxides in decidua basalis in women with preeclampsia. Am J Obstet Gynecol. 1999;180(3 pt 1):587-592.
61. Walsh SW, Vaughan JE, Wang Y, Roberts LJ II. Placental isoprostane is signifcantly increased in preeclampsia. FASEB J. 2000;14:1289-1296.
62. Myatt L, Cui X. Oxidative stress in the placenta. Histochem Cell Biol. 2004;122:369-382.
63. Chen B, Longtine MS, Sadovsky Y, Nelson DM. Hypoxia downregulates p53 but induces apoptosis and enhances expression of BAD in cultures of human syncytiotrophoblasts. Am J Physiol, Cell Physiol. 2010;299:C968-C976.
64. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1085-R1093.
65. Southcombe J, Tannetta D, Redman C, Sargent I. The immunomodulatory role of syncytiotrophoblast microvesicles. PLoS ONE. 2011;6:e20245.
66. Redman CW, Sargent IL. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta. 2008;29 suppl A:S73-S77.
67. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gesta-tional age. Am J Epidemiol. 2002;155:203-209.
68. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG. 2004;111:298-302.
69. Sibai BM. Management of late preterm and early-term pregnancies complicated by mild gestational hypertension/pre-eclampsia. Semin Perinatol. 2011;35:292-296.
70. Klungsøyr K, Morken NH, Irgens L, Vollset SE, Skjaerven R. Secular trends in the epidemiology of pre-eclampsia throughout 40 years in Norway: prevalence, risk factors and perinatal survival. Paediatr Perinat Epidemiol. 2012;26:190-198.
71. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169:1000-1006.
72. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799.
73. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
74. Wikström AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112:1486-1491.
75. Ness RB, Hubel CA. Risk for coronary artery disease and morbid pre-eclampsia: a commentary. Ann Epidemiol. 2005;15:726-733.
76. Mongraw-Chaffn ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166-171.
77. Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, Harlap S. Long-term mortality after preeclampsia. Epidemiology. 2005;16:206-215.
78. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213-1217.
79. Newstead J, von Dadelszen P, Magee LA. Preeclampsia and future cardiovascular risk. Expert Rev Cardiovasc Ther. 2007;5:283-294.
80. Lazdam M, de la Horra A, Pitcher A, Mannie Z, Diesch J, Trevitt C, Kylintireas I, Contractor H, Singhal A, Lucas A, Neubauer S, Kharbanda R, Alp N, Kelly B, Leeson P. Elevated blood pressure in offspring born premature to hypertensive pregnancy: is endothelial dysfunction the underlying vascular mechanism? Hypertension. 2010;56:159-165.
81. Davis EF, Newton L, Lewandowski AJ, Lazdam M, Kelly BA, Kyriakou T, Leeson P. Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies. Clin Sci. 2012;123:53-72.
82. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Infammation in atherosclerosis: from pathophysiol-ogy to practice. J Am Coll Cardiol. 2009;54:2129-2138.
83. Mehta S, Farmer JA. Obesity and infammation: a new look at an old problem. Curr Atheroscler Rep. 2007;9:134-138.
84. de Luca C, Olefsky JM. Infammation and insulin resistance. FEBS Lett. 2008;582:97-105.
85. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, Knöfer M. Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in frst-trimester villous explant cultures. J Clin Endocrinol Metab. 2004;89:812-822.
86. Murphy DJ, Stirrat GM. Mortality and morbidity associated with early-onset preeclampsia. Hypertens Pregnancy. 2000;19:221-231.
87. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental fndings in women with preeclampsia are gesta-tional age dependent. Am J Obstet Gynecol. 2003;189:1173-1177.
88. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS. Placental lesions associated with maternal under-perfusion are more frequent in early-onset than in late-onset preeclamp-sia. J Perinat Med. 2011;39:641-652.
89. Sebire NJ, Goldin RD, Regan L. Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol. 2005;25:117-118.
90. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from pre-eclampsia and eclampsia. Obstet Gynecol. 2001;97:533-538.
91. Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine-Units. Perinatal outcome in women with recurrent preeclampsia compared with women who develop pre-eclampsia as nulliparas. Am J Obstet Gynecol. 2002;186:422-426.
92. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53:812-818.
93. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008;51:1002-1009.
94. Stekkinger E, Zandstra M, Peeters LL, Spaanderman ME. Early-onset preeclampsia and the prevalence of postpartum metabolic syndrome. Obstet Gynecol. 2009;114:1076-1084.
95. Ihle BU, Long P, Oats J. Early onset pre-eclampsia: recognition of underlying renal disease. BMJ. (Clin Res Ed). 1987;294:79-81.
96. Davis EF, Lazdam M, Lewandowski AJ, Worton SA, Kelly B, Kenworthy Y, Adwani S, Wilkinson AR, McCormick K, Sargent I, Redman C, Leeson P. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics. 2012;129:e1552-e1561.
97. Fugelseth D, Ramstad HB, Kvehaugen AS, Nestaas E, Støylen A, Staff AC. Myocardial function in offspring 5-8years after pregnancy complicated by preeclampsia. Early Hum Dev. 2011;87:531-535.
98. Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med. 2012;25:498-507.
99. Denizot Y, Leguyader A, Cornu E, Laskar M, Orsel I, Vincent C, Nathan N. Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery. J Cardiothorac Surg. 2007;2:38.
100. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta. 2005;26:563-573.
101. Herse F, Fain JN, Janke J, Engeli S, Kuhn C, Frey N, Weich HA, Bergmann A, Kappert K, Karumanchi SA, Luft FC, Muller DN, Staff AC, Dechend R. Adipose tissue-derived soluble fms-like tyrosine kinase 1 is an obesity-relevant endogenous paracrine adipokine. Hypertension. 2011;58:37-42.
102. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770-775.
103. Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn. 2010;30:191-197.
104. Wa Law L, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY. Serum placental growth factor and fms-like tyrosine kinase 1 during frst trimester in Chinese women with pre-eclampsia- A case-control study. J Matern Fetal Neonatal Med. 2011;24:808-811.
105. Chen G, Zhang L, Jin X, Zhou Y, Niu J, Chen J, Gu Y. Effects of angio-genic factors, antagonists, and podocyte injury on development of protein-uria in preeclampsia. Reprod Sci. Epub ahead of print September 18, 2012.
106. Boucoiran I, Thissier-Levy S, Wu Y, Wei SQ, Luo ZC, Delvin E, Fraser WD, Audibert F. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. Am J Perinatol. Epub ahead of print December 3, 2012.
107. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 1991;88:9267-9271.
108. Iwasaki H, Kawamoto A, Tjwa M, Horii M, Hayashi S, Oyamada A, Matsumoto T, Suehiro S, Carmeliet P, Asahara T. PlGF repairs myocar-dial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS ONE. 2011;6:e24872.
109. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44:1-9.
110. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angio-genic and infammatory disorders. J Thromb Haemost. 2003;1:1356-1370.
111. Accornero F, van Berlo JH, Benard MJ, Lorenz JN, Carmeliet P, Molkentin JD. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res. 2011;109:272-280.
112. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W, Murphy BJ. Placenta growth factor gene expression is induced by hypoxia in fbroblasts: a central role for metal transcription factor-1. Cancer Res. 2001;61:2696-2703.
113. Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol. 2006;169:1167-1182.
114. Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension. 2011;58:63-69.
115. Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, Simoons ML, Boersma E; CAPTURE Investigators. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:307-311.
116. Iwama H, Uemura S, Naya N, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol. 2006;47:1559-1567.
117. Hemmeryckx B, van Bree R, Van Hoef B, Vercruysse L, Lijnen HR, Verhaeghe J. Adverse adipose phenotype and hyperinsulinemia in gravid mice defcient in placental growth factor. Endocrinology. 2008;149:2176-2183.
118. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44:1-9.
119. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
120. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H, Ahmed A. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors. 1996;13:243-250, color plates I.
121. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta. 1997;18:657-665.
122. Depoix C, Tee MK, Taylor RN. Molecular regulation of human placental growth factor (PlGF) gene expression in placental villi and trophoblast cells is mediated via the protein kinase a pathway. Reprod Sci. 2011;18:219-228.
123. Chang M, Mukherjea D, Gobble RM, Groesch KA, Torry RJ, Torry DS. Glial cell missing 1 regulates placental growth factor (PGF) gene transcription in human trophoblast. Biol Reprod. 2008;78:841-851.
124. Cramer M, Nagy I, Murphy BJ, Gassmann M, Hottiger MO, Georgiev O, Schaffner W. NF-κB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol Chem. 2005;386:865-872.
125. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9:936-943.
126. Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: two pleio-tropic growth factors with distinct roles in development and homeosta-sis. Cell Tissue Res. 2003;314:5-14.
127. Schneider H. Oxygenation of the placental-fetal unit in humans. Respir Physiol Neurobiol. 2011;178:51-58.
128. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble FLT1 sensitizes endothelial cells to infammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res. 2011;89:671-679.
129. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267:26031-26037.
130. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705-10709.
131. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608.
132. Reuvekamp A, Velsing-Aarts F V, Poulina IE, Capello JJ, Duits AJ. Selective defcit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1999;106:1019-1022.
133. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (pla-cental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9-23.
134. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclamp-sia. Am J Obstet Gynecol. 2001;184:1267-1272.
135. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, Maynard SE. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med. 2012;25:2651-2657.
136. Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012;60:451-458.
137. Reyes LM, García RG, Ruiz SL, Broadhurst D, Aroca G, Davidge ST, López-Jaramillo P. Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country. Growth Factors. 2012;30:158-166.
138. Faupel-Badger JM, Wang Y, Staff AC, Karumanchi SA, Stanczyk FZ, Pollak M, Hoover RN, Troisi R. Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes Control. 2012;23:779-784.
139. Perni U, Sison C, Sharma V, Helseth G, Hawfeld A, Suthanthiran M, August P. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012;59:740-746.
140. Molvarec A, Szarka A, Walentin S, Beko G, Karádi I, Prohászka Z, Rigó J Jr. Serum heat shock protein 70 levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in women with preeclampsia. Clin Chim Acta. 2011;412:1957-1962.
141. Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, Cotton DB, Sorokin Y, Karumanchi SA. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol. 2011;204:152. e1-152.e9.
142. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigó J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res. 2010;33:892-898.
143. Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res. 2010;33:561-567.
144. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y. Different profles of circulating angiogenic factors and adipocyto-kines between early-and late-onset pre-eclampsia. BJOG. 2010;117:314-320.
145. Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patrício B, Quintanilha A, Santos-Silva A. Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors. 2009;27:345-351.
146. Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, Rana S. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med. 2010;23:366-370.
147. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of pre-eclampsia. Am J Obstet Gynecol. 2010;202:161.e1-161.e11.
148. Bersinger NA, Groome N, Muttukrishna S. Pregnancy-associated and placental proteins in the placental tissue of normal pregnant women and patients with pre-eclampsia at term. Eur J Endocrinol. 2002;147:785-793.
149. Staff A. Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertension. 2010;1:28-42.
150. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E; EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012;119:778-787.
151. Torry DS, Mukherjea D, Arroyo J, Torry RJ. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig. 2003;10:178-188.
152. Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K, Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151-159.
153. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction? Am J Obstet Gynecol. 2012;206:163.e1-163.e7.
154. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005;90:4895-4903.
155. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci. 2007;112:51-57.
156. Powers RW, Roberts JM, Plymire DA, Pucci D, Datwyler SA, Laird DM, Sogin DC, Jeyabalan A, Hubel CA, Gandley RE. Low placental growth factor across pregnancy identifes a subset of women with pre-term preeclampsia: type 1 versus type 2 preeclampsia? Hypertension. 2012;60:239-246.
157. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469.e1-469.e8.
158. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol. 2010;202:40.e1-40.e7.
159. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:734-741.
160. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension. 2007;49:604-611.
161. Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, Kellems RE, Xia Y. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension. 2012;60:712-721.
162. Sugulle M, Herse F, Hering L, Mockel M, Dechend R, Staff AC. Cardiovascular biomarker midregional proatrial natriuretic peptide during and after preeclamptic pregnancies. Hypertension. 2012;59:395-401.